UBS Restarts Coverage of Icon PLC (ICLR) with Neutral Rating and
UBS resumed coverage of Icon PLC (ICLR) with a Neutral rating and $195 price target, citing sector growth but client-specific challenges. GuruFocus estimates ICLR's intrinsic value at $205.65, indicating a 17.2% undervaluation. The stock has a high GF Score of 94/100, with strong valuation and profitability but moderate financial strength. Insiders have sold $4.0M in shares over the past year.
How this was made
The 30-second read
Why it matters
UBS's neutral rating and $195 target provide a fresh valuation reference, potentially influencing short‑term trading and sector sentiment.
Market read
Analyst coverage restart offers new price guidance, creating a modest trading opportunity for ICLR.
What to watch
Insider net selling of $4 million and moderate financial strength (Altman Z‑Score 1.87) could weigh on price.
Background
Icon PLC is an Irish contract research organization serving pharma and biotech clients, with a market cap of $13.14 bn.
Ticker impact
UBS restarted coverage of Icon PLC with a Neutral rating and set a new price target of $195, indicating a fresh analyst opinion.
potential modest upside as the market prices in the $195 target
The new target is above the current price of $170.35, suggesting investors may bid the stock toward $195 if the rating is accepted.
Market effects
Reinstating coverage may signal broader optimism for the CRO sector, potentially lifting peer valuations.
Limited to U.S. and European markets where Icon PLC trades.
Modest, as the CRO industry is niche but growing globally.
Counterpoint
The high trailing P/E of 309x suggests the stock may be overvalued despite the target, limiting upside.
Key entities
- companyIcon PLC
Irish CRO listed on NASDAQ under ICLR.
- analystUBS
Investment bank that restarted coverage of Icon PLC.